Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193410 | 0.91 | GSK3B (0.49) | GSK3BCNR1CNR2 | |
| SCHEMBL1187458 | 0.88 | GSK3B (0.39) | GSK3B | |
| SCHEMBL1187692 | 0.86 | GSK3B (0.43) | GSK3B | |
| SCHEMBL2193423 | 0.84 | GSK3B (0.54) | GSK3BCNR1CNR2 | |
| SCHEMBL15090820 | 0.81 | GSK3B (0.41) | GSK3B | |
| SCHEMBL1186321 | 0.78 | GSK3B (0.45) | GSK3B | |
| SCHEMBL2194978 | 0.78 | GSK3B (0.50) | GSK3B | |
| SCHEMBL1186145 | 0.77 | GSK3B (0.49) | GSK3B | |
| SCHEMBL1342789 | 0.76 | STAT3 (0.40) | GSK3B | |
| SCHEMBL1185600 | 0.74 | GSK3B (0.40) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| EP-2203458-B1 | CYANOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2203458-A2 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009035634-A2 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | GSK3B 2/4885CNR1 3475/4885CNR2 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.